


Disease Reversal and Regeneration Through Angiogenesis






Aging and Cognitive Decline






Your Stem Cells Need Adequate Blood Perfusion to Divide and Mature






Angiogenesis is Natural Process





Therapeutic Angiogenesis as a New Treatment for Perfusion-Related Diseases

Angiogenesis: The Growth of New Blood Vessels From Preexisting Vessels









Over 75 human diseases are a result of impaired perfusion


What is FGF-1?

FGF-1 is a Natural Growth Factor In Your Body that is a Potent Stimulator of New Blood Vessel Growth (Angiogenesis)











Major Manifestations of Vascular Disease

A Frequent Complication of Diabetes: The Diabetic Foot Ulcer




Phase IIb Healing Examples



Results of Phase IIb Trial in Diabetic Ulcers

- 100% closure of wounds within 5 months or less
- 57% complete closure at
 8 weeks, versus 0% for
 the placebo group





Coronary Artery Disease



Recognition of FGF-1's Clinical Success ABC News Clip Reports a Breakthrough Therapy for Severe Heart Disease










Zhittya Will Initiate US FDA-Authorized Clinical Trials in these Three Medical Indications in 2020

We will basically repeat the same design as the previous successful clinical trials.

- Coronary artery disease US Phase I
- Diabetic foot ulcers US Phase IIb
- Venous leg ulcers US Phase II




The Brain is Incredibly Vascularized





The "Neurovascular Unit"




Trends in Pharmacological Sciences




Red Blood Cells Traveling Through a Capillary Single File

















FGF-1 Decreases
Volume of Stroke
in Rats

Placebo

FGF-treated





Revascularization of the brain after a stroke






Parkinson's Disease




Dopamine Producing Neurons in the Brain are Affected by Parkinson's Disease






Regional Blood Perfusion (by functional MRI) in Healthy Adults and Subjects with Parkinson's Disease and Stroke






Decline of Dopamine Neurons in Parkinson's



MRI Scan Shows Perfusion Defects (Parkinson's Patient with Dementia)








Monkey Model of Parkinson's Disease






Disease Reversal in the Brains of Monkeys with Parkinson's Disease: Regeneration of New Neurons

New Dopamine Neurons (stain brown)


No FGF-1 \rightarrow

FGF-1 Treated →





FGF-1 decreases the presence of aggregated α synuclein in the nigrostriatal region





Zhittya Will Initiate "Proof of Concept" Clinical Trials in 2020

Clinical Trials are under review by the US FDA, as well as in Mexico and Estonia

The trials will answer:

Is the medicine safe in the brain?

Is the medicine viable in these indications?

- Parkinson's disease
- ALS (Lou Gehrig's disease)
- Alzheimer's disease
- Multiple sclerosis
- Chronic depression
- Stroke recovery



If you want to participate in the clinical trials or want more information on medical indications we will be addressing:

Website: zhittyaregenerativemedicine.com

Office phone: (702) 802-9855



Thank you!

